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What’s already known about this topic? 
 
 Vitiligo can have a profound psychosocial impact  
 People with vitiligo are more likely to suffer depression than those without vitiligo 
 
What does this study add? 
 People with vitiligo experience a range of psychological symptoms or disorders.  
 Approximately one in four people with vitiligo suffer from depression however the 
prevalence of anxiety is unclear as it varies substantially according to the screening 
tool used.  
 Validation of psychological outcome screening tools in the field of dermatology 
should be considered. 
 
 
 
  
 
 
 
 
Abstract   
Background: Vitiligo is a chronic disorder causing skin depigmentation with global 
prevalence varying from 0.2 to 1.8%. UK guidelines recommend assessment of 
psychological state during clinical evaluation of vitiligo. However, the prevalence of 
psychological co-morbidity in people with vitiligo has not been described. 
Objectives: We aimed to establish the prevalence of psychological symptoms or disorders 
in people with vitiligo and describe the outcome measures used. 
Methods: We performed a comprehensive search of MEDLINE, Embase, CINAHL and 
PsychInfo to identify observational studies assessing the prevalence of psychological 
symptoms or disorders (December 2016). DerSimonian and Lard random-effects models 
were utilized to estimate the overall pooled prevalence. 
Results: We identified 29 studies with 2530 people with vitiligo. Most studies included a 
measure of either depression (n=25) or anxiety (n=13).The commonest tools were the 
Hospital Anxiety and Depression Scale and the Centre for Epidemiology Studies Depression 
Scale. Ten studies provided information on thirteen other psychological outcomes. Pooled 
prevalence using depression-specific and anxiety-specific questionnaires was 0.29 (95%CI 
0.21, 0.38) and 0.33 (95%CI 0.18, 0.49) respectively. Prevalence was lower for clinically 
diagnosed depression (0.21; 95%CI 0.15, 0.28) and anxiety (0.15; 95%CI 0.06, 0.24). 
When non-specific tools were used the prevalence remained similar for depression (0.27; 
95%CI 0.08, 0.46) but increased for anxiety (0.46; 95% CI 0.39, 0.52). High 
heterogeneity was observed. 
Conclusions: A range of psychological outcomes are common in people with vitiligo. The 
prevalence of anxiety was influenced by type of screening tool, suggesting validation of 
psychological outcome screening tools in the field of dermatology. .  
 
 
 
 
 
 
 
 
 
 
 Introduction 
Vitiligo is an acquired chronic disorder of skin pigmentation caused by the selective 
destruction of melanocytes.1 It causes milky-white patches or macules on the skin, most 
commonly in exposed areas of the body such as the hands and face.2 Vitiligo occurs equally 
in both genders and all ethnicities, and may develop at any age, although it most 
commonly presents in children and young adults.1 The global prevalence varies from 0.2 
to 1.8%.3 
 
The aetiology of vitiligo is not fully understood. Autoimmune, genetic and environmental 
factors probably combine to give a mixed aetiology.4-6 A recent Cochrane systematic 
review concluded that there is currently no cure for the condition although there are 
various treatments/interventions available to manage vitiligo such as topical 
corticosteroids, calcineurin inhibitors, phototherapy and camouflage.7 
 
Although vitiligo is typically asymptomatic it may substantially affect the psychological 
wellbeing of people living with the condition.8-12 This may be due to the burden associated 
with the visibility of vitiligo and its consequent impact on interactions with others.13 
Another reason may be the unpredictable prognosis and the current lack of a cure. The 
British Association of Dermatologists recommends assessment of the psychological state 
and quality of life during clinical evaluation of people with vitiligo.2 Furthermore, a recent 
systematic review has shown that people with vitiligo are significantly more likely to suffer 
from depression and impaired general health, compared to those without vitiligo.14 
However, there is a lack of knowledge of the other types of psychological symptoms or 
disorders that people with vitiligo experience. Such information may help the development 
of future trials of psychological interventions in people with vitiligo. A Cochrane Review 
found only one randomised controlled trial on the effectiveness of psychological 
interventions in people with vitiligo.7 Evaluating the effectiveness of psychological 
interventions for this patient group was one of the top ten research priorities identified by 
the James Lind Alliance’s vitiligo Priority Setting Partnership.15 
To date, no systematic review on the prevalence of psychological co-morbidity in people 
with vitiligo has been conducted. Therefore, this review aimed to synthesise all available 
evidence from observational studies on the prevalence of psychological symptoms or 
disorders in people living with vitiligo.  
Methods 
The study protocol was registered with National Institute for Health Research International 
prospective register of systematic reviews (PROSPERO) on 21st of March 2016 and is 
available at http://www.crd.york.ac.uk/prospero (registration number 
CRD42016036193). We initially planned to look at two primary outcomes (i) psychological 
co-morbidity and (ii) quality of life within the same study. However, due to the number of 
studies found and the theoretical difference between quality of life and psychological 
symptoms or disorders, it was decided it would be more appropriate to assess these 
outcomes separately. The systematic review on quality of life in people with vitiligo has 
been published.16 The methods used for this review were reported in accordance with the 
PRISMA statement.17 
 
Literature search 
On 21st of December 2016, a literature search in MEDLINE (OVID), Embase (OVID), 
PsychINFO and CINAHL was performed. Records from the inception of each database were 
accessed. The search strategy was developed by O.O. after consultation with an 
information specialist with experience in dermatology (D.G.). The strategy included the 
search terms ‘vitiligo’, ‘leucoderma’, ‘leukoderma’, ‘psychology’, ‘depression’, ‘anxiety’ and 
‘mental health’ (see Supplementary Table 1). The use of these search terms was appeared 
sufficient in capturing psychological co-morbidity and it was consequently deemed as 
unnecessary to conduct searches using all known diagnostic categories. 
Grey literature was searched at this website:  
http://www.bl.uk/reshelp/findhelprestype/theses/ethos/index.html. Reference tracking of key 
papers and citation searching in Google Scholar were also conducted. 
  
 
Eligibility Criteria 
We included observational studies (cohort, case-control, cross-sectional and case series) 
that reported data on the prevalence or incidence of any psychological outcome in people 
with vitiligo. Ecological studies, policy statements, editorials/reviews and randomised 
controlled clinical trials involving any form of intervention were excluded. Trials were 
excluded as people included in trials may not be representative of people from everyday 
clinical practice and to keep this work manageable within the timeframe available.18 There 
was no restriction on age, sex, type of vitiligo, ethnicity or publication language.  Vitiligo 
had to have been diagnosed clinically by a clinician or dermatologist. The psychological 
outcomes of interest were any form of psychological symptom or disorder that was either 
self-reported or clinically diagnosed.  
 
 
Selection 
Two authors (O.O., S.R.) independently assessed studies for eligibility using a two-stage 
sifting process. The titles and abstracts were reviewed simultaneously and subsequently 
the full text copies of potentially relevant studies were screened. Results of the 
independent assessments by each author were compared and differences were resolved 
through discussion.  A citation search using Google Scholar and reference lists of key 
papers were searched by hand for relevant studies to increase the sensitivity of our search.  
 
 
Data extraction 
Two authors (O.O., L.H.) independently extracted information from the included studies 
using a piloted template and any disparity was resolved by discussion. The translation and 
data extraction of the Spanish, French and Italian papers were conducted by researchers 
proficient in these languages.  
 
Evaluation of methodological quality of the included studies 
The methodological quality of the included studies was evaluated by combining and 
adapting the Newcastle-Ottawa19 and the National Heart Lung and Blood Institute scales.20-
21 Modification of the Newcastle-Ottawa scale was required due to concerns about the 
vagueness of decision rules in relation to the focus of our review and the National Heart 
Lung and Blood Institute scale was used to include a tool for cross-sectional studies 
(Supplementary Tables 2a & 2b). Quality assessment was conducted independently by 
three of the researchers (O.O., L.H., S.R.). A score of ≥70% was rated as good, 50-69% 
as fair and <50% as poor. 
 
Data Analysis 
Pooled prevalence (expressed as a proportion) of depression and anxiety according to 
depression/anxiety-specific, non-depression/non-anxiety specific questionnaires and 
psychiatric diagnosis was calculated.  For controlled studies, studies were pooled to 
determine relative risk when there were a sufficient number of studies ≥3. Random-effects 
model of DerSimonian and Lard was used to account for variance between and within 
studies.22 Heterogeneity between studies was assessed using I-squared statistic, with 
values of 25%, 50% and 75% considered low, moderate and high heterogeneity 
respectively.23 All analyses were performed using Stata version 14.0 (StataCorp, College 
Station, TX).  For psychological outcomes which were not included in the meta-analysis, a 
narrative synthesis was conducted. 
Results  
Study selection 
The execution of the search strategy initially resulted in 1000 studies after duplicates were 
removed. After screening titles and abstracts, 98 studies were obtained for full review. Of 
these, 24 fulfilled the inclusion criteria for the systematic review (Figure 1). A search 
through the grey literature database identified no further studies. However, a citation 
search using Google Scholar identified two further eligible papers and reference tracking 
identified three eligible studies, giving a total of 29 included studies.  
 
 
Description of included studies 
Table 1 summarises the general characteristics of the 29 eligible studies (2530 vitiligo 
patients in total). Twenty-six of the studies were cross-sectional and three studies were 
case-control. Eleven studies included comparator groups; these consisted of participants 
diagnosed with other dermatological diseases such as acne, psoriasis, albinism, alopecia 
areata, skin cancer, neurodermatitis, eczema, or healthy participants that were either 
related to or accompanying the participants to the clinics/hospitals, or hospital staff. There 
were seven studies conducted in Europe, thirteen studies from Asia, three studies from 
the Americas, three studies from the Middle East and the remaining three studies were 
from Africa. Sample size ranged from 9 to 326 people. The participants were recruited 
from either hospitals (n=24) or dermatology clinics (n=4) or from both (n=1).  
 
Psychological outcomes  
The most common psychological outcomes in the studies reviewed was depression (n=25 
studies) (Table 2). Anxiety was reported in 13 studies; two of these reported generalised 
anxiety (Table 3). Ten studies reported on 13 other less commonly reported outcomes: 
substance abuse, suicidal attempts, panic disorder, social phobia, dysthymic disorder, 
adjustment disorder, alcohol addiction, asthenia, interpersonal conflict, insomnia, 
obsessive compulsive disorder, specific phobia and agoraphobia. (Table 4). The focus of 
our analysis is on depression and anxiety as these are the two most common outcomes.  
 
Outcome measurement tools 
Nineteen different outcome tools were used in total including depression-specific or  
anxiety-specific questionnaires (e.g. Centre for Epidemiology Studies Depression 
Screening Index (CES-D) or ) non-depression or non-anxiety specific questionnaires (e.g. 
General Heath Questionnaire (GHQ)) and clinical diagnostic tools (e.g. International 
Classification of Disease 10th version (ICD-10)) (Table 1). Of the 29 included studies, only 
nine26,28-30,33,34,40,42,51 included clinical assessment (only one study reported the use of a 
structured interview42), and four of these did so after screening with the general health 
questionnaire (Table 1).28-30,40 
 
Quality of studies 
A score of ≥70% was rated as good, 50-69% as fair and <50% as poor. Of the 29 studies, 
n=4 (14%) were of poor quality, n=13 (45%) were of fair quality and n=12 (41%) of were 
of good quality (Table 1).   
 
Prevalence of depression 
A total of 25 studies including 2071 vitiligo patients reported data on the prevalence of 
depression. Table 2 summarises the general characteristics of each study. A total of 
fourteen different outcome tools were used to assess depression including five depression-
specific tools (n=11 studies) and four non-depression specific tools (n=4 studies); clinical 
examination was conducted in nine studies using the ICD-10 or Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (DSM-IV) or tool not stated. One study used a 
questionnaire but did not provide further details (and has been classified as a non-
depression specific questionnaire). In two studies clinical examination was conducted only 
for patients within a certain GHQ threshold (this is why the total number of patients in 
Table 2 is greater than 2071).28,30 
 
The pooled prevalence of depression among vitiligo patients based on depression-specific 
questionnaires was 0.29 (95% CI 0.21, 0.38), as shown in Figure 2. There was substantial 
heterogeneity between the studies (I-squared=89%, p<0.001). Using non-depression 
specific questionnaires, the pooled prevalence was similar 0.27 (95% CI 0.08, 0.46) with 
higher heterogeneity (I-squared=97.5%, p<0.001); using clinical diagnosis, the pooled 
prevalence was lower 0.21 (95% CI 0.15, 0.28) with lower heterogeneity (I-squared 
66.7%, p=0.004). 
 
Eleven studies presented the prevalence of depression in a comparator group. The most 
common comparator was people with psoriasis with five studies including 172 vitiligo 
patients. Only the study conducted by Mattoo et al.28, matched the control and the vitiligo 
participants (by sex and education). The overall risk of depression was less in people with 
vitiligo compared to those with psoriasis; pooled relative risk was 0.66 (95% CI 0.48, 
0.90); there was no heterogeneity (Figure 3).  
The second most common comparator was healthy controls (n=4 studies; but only two of 
these reported the prevalence of depression in the comparator groups).42,51  In both 
studies, the prevalence of depression was higher in vitiligo patients compared to the 
healthy controls. The healthy controls and vitiligo participants were similar in age and sex 
in the study conducted by Balaban et al.42 but not in the study by Karia et al.51 
 
Prevalence of anxiety 
Thirteen studies including 866 vitiligo patients reported data on the prevalence of anxiety. 
Table 3 summarises the general characteristics of each study. A total of five different 
outcome tools were used to assess this disorder including three anxiety-specific tools (n=5 
studies) and two non-anxiety tools (n=2 studies); and clinical examination by a 
psychiatrist was conducted in six studies.   
 
The pooled prevalence of anxiety among vitiligo patients based on anxiety-specific 
questionnaires was 0.33 (95% CI 0.18, 0.49), as shown in Figure 4. There was substantial 
heterogeneity between the studies (I-squared=89.2%, p<0.001). Using non-anxiety 
specific questionnaires, the pooled prevalence was higher at 0.46 (95% CI 0.39, 0.52) 
with higher heterogeneity (I-squared=96.2%, p<0.001). Using clinical diagnosis, the 
prevalence was substantially lower at 0.15 (95% CI 0.06, 0.24) but heterogeneity was still 
very high (I-squared 88.7%, p<0.001). 
 
Nine studies presented the prevalence of anxiety in a comparator group. The most common 
comparator was psoriasis with four studies including 119 vitiligo patients.  Only the study 
conducted by Mattoo et al.28 matched the control group and the vitiligo participants by 
sex.  The pooled relative risk of anxiety in people with vitiligo compared to those with 
psoriasis was 0.80 (95% CI 0.57, 1.13) and there was no heterogeneity (Figure 5).  
The second most common comparator was healthy controls.42,51 The prevalence of anxiety 
was higher in vitiligo patients compared to the healthy controls. The control group was 
matched on age and sex in the study conducted by Balaban et al.42 
 
Prevalence of other psychological outcomes 
Ten studies including 577 patients with vitiligo provided data on 13 less commonly 
reported psychologicaloutcomes . Table 4 summarises the general characteristics of each 
study. The majority of these studies were based in Asia (n=6 studies). The most commonly 
reported psychological outcome was social phobia (n=4 studies); the prevalence varied 
from 2.4% to 67.9%; two studies used psychiatric clinical examination and two used self-
reported questionnaires.  
Seven studies presented the prevalence of other psychological outcomes in a comparator 
group. The most common comparator was people with psoriasis (n=4 studies). Apart from 
dysthymic disorder, the prevalence of the psychological outcomes was the same or lower, 
in those with vitiligo compared to those with psoriasis. Only two studies matched the 
vitiligo and comparator groups. Matto et al.28 matched in terms of sex and education while 
Balaban et al.42 matched on age and sex. 
  
Discussion 
Main findings 
To our knowledge, this is the first systematic review that synthesises the prevalence of 
different psychological outcomes in people with vitiligo. We demonstrated that people with 
vitiligo experience a range of outcomes on the spectrum of psychological symptoms or 
disorders including anxiety, substance abuse and suicidal attempts..  The two most 
commonly reported outcomes were depression and anxiety which were assessed using 
either self-reported questionnaires or clinical diagnosis made by a psychiatrist. 
 
Historically vitiligo has been classed as a cosmetic problem; this is clearly not the case.53 
Qualitative studies indicate that vitiligo can have a huge psychological burden on people. 
54,55 According to our review, approximately a quarter of vitiligo patients reported 
depression symptoms using depression-specific or general/mental-health questionnaires 
and almost a fifth of them had clinical depression. However, they were significantly less 
likely to show symptoms of depression than people with psoriasis. The pooled prevalence 
of anxiety did differ depending on whether the diagnosis was made using anxiety-specific 
or general/mental health questionnaires ranging from 33% to 46%. However, it was 
substantially lower when diagnosed clinically (15%). Similar to depression, the risk of 
anxiety was lower in those with vitiligo compared to those with psoriasis, but this result 
was not statistically significant. 
 
Strengths and Limitations  
The major strength of this review is the broad overview of the different psychological 
outcomes experienced by people with vitiligo. Searching four databases, including 
PsychInfo, helped ensure our search was comprehensive and improves on similar previous 
published work.14 Including non-English papers, as far as possible, has reduced the 
potential for bias. We have also been able to conduct a meta-analysis to quantify the 
difference in depression and anxiety between people with vitiligo and those with psoriasis. 
Such information has not been reported previously. 
 
The main limitation of this review is the high heterogeneity between the included studies. 
This may be due to the broad inclusion criteria. We have attempted to address study 
heterogeneity by employing a random-effects model. However, due to substantial 
heterogeneity, the results may not be generalizable to all vitiligo patients. Information on 
the type and severity of vitiligo, which can be potential sources of heterogeneity, were not 
available in most studies.  Also, the majority of the included studies did not have adequate 
controls, making the results susceptible to the effect of confounding factors. All studies 
were hospital or clinic-based, which could also result in selection bias. Due to the small 
number of studies, we were not able to conduct separate meta-analyses for different 
measurement tools when comparing the prevalence of depression and anxiety to those 
seen in people with psoriasis. We were also limited to comparing vitiligo with psoriasis and 
not other skin conditions, or healthy controls. Finally, we had insufficient studies to assess 
publication bias. 
 
Comparison with other studies 
The most relevant study to compare our findings with is that of Lai et al.14 The authors 
conducted a systematic review to investigate the prevalence of depression and general 
health in people with vitiligo worldwide. Among studies reporting the prevalence of 
depression based on ICD codes, the pooled prevalence of depression among vitiligo 
patients was 0.253 (95% CI: 0.161 to 0.345). Using DSM-IV criteria, the pooled 
prevalence decreased to 0.122 (95% CI: 0.046 to 0.197) and using self-reported 
questionnaires the prevalence of depressive symptoms was 0.336 (95% CI: 0.248-0.424). 
Their results, like ours, showed that use of questionnaires provided higher estimates of 
prevalence than clinical diagnosis. This is because questionnaires such as HADS (Hospital 
Anxiety and Depression Scale) and CES-D are often used to measure the presence of 
depressive symptomatology rather than the presence of the full criteria for a diagnosis of 
clinical depression to be made.  The same rational is applicable in the explanation as to 
why the prevalence of clinically diagnosed anxiety that we found was substantially lower 
than that reported by questionnaires.  
Lai et al. combined broad mental-health and depression-specific self-reported 
questionnaires, which may explain why their pooled estimate of the risk of depression was 
higher than ours (0.34 vs. 0.29). We only combined questionnaires specific to measuring 
depression, as we believe this provides a more accurate estimate.  We did not report 
prevalence separately for  ICD and DSM-IV tools, as Lai et al. did, but reported prevalence  
for clinical diagnosis overall as it was unclear in some papers which tool was used.26,34 
Finally, similar to Lai et al. we report that those with vitiligo are at higher risk of depression 
than healthy controls (without adjustment for confounders). Lai et al. did not compare the 
prevalence of depression in people with vitiligo with those with other skin conditions. 
 
 
Research implications  
This review has established that there are currently no large or population-based studies 
exploring the psychological impact of vitiligo. With the current availability of linked large 
routinely collected healthcare datasets such as the Clinical Practice Research Datalink and 
Hospital Episode Statistics and Mental Health Dataset54 there is an opportunity for 
researchers to conduct large cost-effective studies at population level with comparable 
controls which will provide more generalizable and less biased results in this field. 
This review has shown the range of psychological screening tools not all of which were 
validated being used. Lack of sensitivity of the measurement tools and variability in the 
tool use may greatly increases the risk of producing inaccurate estimates of the prevalence 
of anxiety. . It has been argued that the Patient Health Questionnaire-version 9 and the 
Generalised Anxiety Disorder Assessment-version 7 are useful pragmatic measures as they 
are free and widely used in primary care to assess depression and anxiety amongst people 
with skin conditions.55-56 Nevertheless, our findings indicate that there is a case for 
developing dermatology specific validated scales. 
 
Clinical implications  
As approximately one in four people with vitiligo appear to have depression and at least 
one in seven have anxiety, assessment of psychological state during clinical evaluation of 
vitiligo patients, as suggested by the British Association of Dermatology guidelines2, is 
essential. The same can be said for clinical evaluation of people with other skin 
conditions. 
 
Conclusion 
People living with vitiligo experience a range of psychologicalsymptoms or disorders. The 
prevalence of depression did not vary substantially by screening tool whereas the 
prevalence of anxiety did, suggesting the need for dermatological specific validated 
screening tools in this group of patients. Population-based studies in this field are also 
required to provide more generalizable results. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1: CHARACTERISTICS OF INCLUDED STUDIES 
 
 
STUDY/ 
LOCATION 
STUDY 
DESIGN 
NUMBER OF 
VITILIGO 
PARTICIPA
NTS   
M/F SETTING ADULTS/ 
CHILDREN 
MEAN AGE 
(YEARS) 
 OUTCOME  OUTCOME 
MEASUREMENT 
TOOL  
QUALITY 
RATING 
Porter 1987  (24) 
USA 
 
 
Cross 
Sectional 
326 Not 
stated 
Clinic Adults + 
children  
34   Depression Questionnaire Fair 
 
Delfino 1988 (25) 
Italy 
Case Control 10 5/5 Hospital Adults Not stated  Depression, Psychopathic 
personality, Hysteria 
MMPI Fair 
Vilella 1998 (26) 
Cuba 
Case Control 22 8/14 Hospital Children Not stated  Depression, Anxiety, 
ADHD,  
Clinical examination 
by psychiatrist, 
Machover test 
Poor 
Picardi 2000 (27) 
Italy 
Cross 
Sectional 
32 Not 
stated 
Hospital Adults Not stated  Psychiatric morbidity GHQ 12 (Italian 
version) 
Fair 
Mattoo 2001 (28) 
India 
 
 
Cross 
Sectional 
113  62/51 
 
 
Hospital Not stated 30.1 (SD: 
12.49)  
 
 Adjustment Disorder, 
Depressive episodes, 
Dysthymia 
 
GHQ 12 (Hindi 
version), CPRS (which 
comprises of MADRS 
and ASI), ICD-10 
Good 
Sharma 2001 (29) 
India 
 
Cross 
Sectional 
 30 17/13 Hospital Adults  
 
 
Not stated 
 
 Depression, Anxiety, Sleep 
Disturbance 
GHQ 12 (Hindi 
version) prior to 
Psychiatric assessment 
using DSM – IV 
criteria 
Good 
Mattoo 2002(30)  
India 
 
Cross 
Sectional 
113 62/51 Hospital Adults + 
children 
30.1(SD:12.49)  Adjustment Disorder, 
Depressive episodes 
GHQ 12 (Hindi 
version), CPRS (which 
comprises of MADRS 
and ASI), ICD-10 
Good 
Sampogna 2004 (31) 
Italy 
 
 
Cross 
Sectional 
 
29 
 
Not 
stated 
Hospital  Not Stated Not Stated   
 
Psychiatric morbidity 
 
 
 
GHQ 12 
 
Fair 
Mechri  2006 (32) 
France 
Case Control 60 32/28 Hospital Adults + 
children 
38.9 (SD:25.7)  Depression, Anxiety CPRS(MADRS), HAM- 
A 
Fair 
Ahmed 2007 (33) 
Pakistan 
 
 
Cross 
Sectional 
100 38/62 
  
Hospital Adults + 
children 
24.6 years 
 
 Major Depression. 
Generalized Anxiety, 
Social Phobia,  
Agoraphobia, Sexual 
Dysfunction 
GHQ 12 (urdu version) 
prior to PAS (urdu 
Version) DAQ 
Good 
Arycan 
2008 (34) 
Turkey 
 
 
Cross 
Sectional 
113 53/60 
 
 
Hospital  Adults + 
children 
Males: 29.2, 
Females: 33.4 
 Depression, 
Anxiety, 
Personality Disorder, 
Neurotic symptoms,  
Obsession 
 
Clinical examination 
by psychiatrist  
Poor 
Saleh 2008 (35) 
Egypt 
 
 
Cross 
Sectional 
 
50 25/25 
 
 
 
 
Hospital  Adults Not stated 
 
 Psychiatric morbidity, 
Anxiety, Depression, 
Suicidal thoughts, Suicidal 
attempts 
GHQ 28 (Arabic 
version), Taylor 
manifest anxiety scale 
(Arabic version), SDS 
questionnaire.  
Good 
Sampogna 2008 (36) 
Italy 
Cross 
Sectional 
180 57/123 Clinic Adults + 
children 
Not stated  Depression  GHQ 12 Fair 
Nogueira 2009 (37) 
Brazil 
 
 
Cross 
Sectional 
100 Not 
stated 
Hospital 
 
Adults + 
children 
Not stated  Psychological complaints 
 
 
Questionnaire (cut off 
score not stated) 
Poor 
Osman 2009 (38) 
Sudan 
 
Cross 
Sectional 
111 46/65 
 
 
Hospital Adults + 
children 
Not stated  Psychological morbidity GHQ 12 Good 
AlGhamdi 
2010 (39) 
Saudi Arabia 
Cross 
Sectional 
164 91/70  Hospital Adults + 
children 
27 (SD:13)  Depression, 
Anxiety 
IPQ Good 
 
Bashir 
2010 (40) 
Pakistan 
 
 
 
 
Cross 
Sectional  
 
 
9 
 
Not 
stated 
 
 
 
Hospital 
 
Adults 
 
Not stated 
  
Depression 
 
 
 
GHQ– 12 (Urdu 
version), PSE, ICD-10 
 
Fair 
Choi 2010 (41) 
Korea 
 
 
Cross 
Sectional 
57 27/30 
 
Hospital  Children 15.4 (SD:1.8)  Depression 
 
CES-D 
 
Good 
Balaban 2011 (42) 
Turkey 
 
 
Cross sectional 42 19/23 
 
  
Clinic Adults 39.70 (SD: 
12.90), 
 Major Depression (MD), 
Generalised Anxiety 
Disorder (GAD),  
Dysthymic Disorder, Social 
Phobia, Specific Phobia,  
HADS, SCID -1, LSAS Good 
Chan 2011 (43) 
Singapore 
 
 
Cross 
Sectional 
145 
 
72/73 
 
  
Hospital Adults 47.4 (SD:15.0)  Depression 
 
CES-D 
 
Good 
Yamamoto 2011 (44) 
Japan 
 
 
Cross 
Sectional 
(Pilot) 
54 
 
Not 
stated 
Hospital/Clinic Not stated Not stated  Depression 
 
CES-D 
 
Poor 
Karelson 2012 (45) 
Estonia 
 
 
Cross 
Sectional 
54 22/32 
 
Clinic Not stated 36.6 
 
 Depression, Anxiety, Panic 
disorders, Social Phobia, 
Insomnia 
 
ES-Q Fair 
Centre for Epidemiologic Studies Depression Scale (CES-D), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale f(HAM – A), Hospital Anxiety and Depression Scale (HADS), 
General Health Questionnaire (GHQ) Emotional State Questionnaire (ES-Q), Structured clinical interview for DSM – IV Axis 1 Disorders (Clinical Version) (SCID-1), Liebowitz Social Anxiety Scale 
(LSAS), Present State Examination (PSE), Sheehan Disability Scale (SDS), Illness Perception Questionnaire (IPQ), Taylor Manifest Anxiety Scale (TMAS), Self rating Depression Scale (SDS), 
Rosenberg Self Esteem Scale (RSES), Dysfunction Analysis Questionnaire (DAQ), Impact of Skin Disease Scale (IMPACT), Comprehensive Psychopathological Rating Scale (CPRS) (which comprises 
of Montgomery Asberg Depression Rating Scale (MADRS) and Anxiety Severity Index (ASI)),  Multi-factorial Method for Personality Investigations(MMPI), International statistical Classification of 
Disease version 10 (ICD)-10, Psychiatric Assessment Schedule (PAS), Standard Deviation (SD). 
 
 
 
 
 
Chan  
2013 (46) 
Singapore 
Cross 
Sectional 
222 105/11
7 
 
  
Hospital  Adults 48.4 (SD:14.9)  Depressive Symptoms 
 
 
 
CES-D 
 
Good 
Ajose  
2014 (47) 
Nigeria 
 
 
 
Cross 
Sectional 
 
102 51/51 Hospital Adults + 
children 
35.9  (SD: 
13.65) 
 
 Depression. Anxiety HADS Good 
Ramakrishna 2014 (48) 
India 
 
 
Cross 
Sectional 
53 12/41 
 
 
Hospital Not stated Not stated  Major Depressive 
Disorder,  
Social Phobia, Panic 
Disorder, Obsessive 
Compulsive Disorder, 
Social Phobia and major 
Depression 
 
HDRS Fair 
Alshahwan 2015 (49) 
Saudi Arabia 
Cross 
Sectional 
64 Not 
stated 
 
 
 
Hospital Adults Not stated  Depression, Anxiety 
 
HADS Fair 
Mahsa 2015 (50) 
Iran 
Cross 
Sectional 
110 48/62 Hospital Adults + 
children 
Not stated  Depression HDRS Fair 
Karia  2015 (51) 
India 
 
 
Cross 
Sectional 
50 22/28 
 
 
Hospital Adults 33.60  Depression, Anxiety 
disorder, Schizophrenia,  
Substance Abuse 
 
GHQ 28, DSM – IV Fair 
Tsintsadze 2015 (52) 
Georgia 
 
 
Cross 
Sectional 
 
15 9/6 
 
 
Hospital Adults + 
children 
Not stated  Anxiety, Depression 
 
 
 
HADS Fair 
  
 
TABLE 2: PREVALENCE OF DEPRESSION 
OUTCOME SCREENING TOOL STUDY COUNTRY SAMPLE SIZE 
(VITILIGO 
PARTICIPANTS) 
PREVALENCE COMPARATOR  SAMPLE SIZE 
(COMPARATORS) 
PREVALENCE IN 
COMPARATORS 
HADS Ajose  2014 (47) Nigeria 102 30% Albinism with severe skin 
complications  
34 27% 
Albinism without severe 
skin complications 
53 2% 
Alshahwan  2015 (49) Saudi 
Arabia 
64 14.1%    
Tsintsadze  2015 (52) Georgia 15 60% Acne 37 54% 
Alopecia Areata 28 50% 
Psoriasis 36 69.4% 
Neurodermatitis 18 18% 
Scabies 23 21.7% 
Eczema 30 56.6% 
DSM-IV/SCID-1 Balaban  2011(42) Turkey 42 14.3% Healthy controls 33 6.1% 
 Sharma   2001 (31) India 30 10% Psoriasis 30 23.3% 
 Karia   2015 (51) 
 
India 50 20% Healthy controls 50 0% 
CES-D Choi  2010 (41) Korea 57 22.8%    
Chan  2011 (43) Singapore 145 17.2%    
Yamamoto  2011 (44) Japan 54 27.8%    
Chan  2013 (46) Singapore 222 16.2%    
GHQ Sampogna  2008 (36) Italy 180 31%    
ICD-10 Mattoo  2001 (28) 
 
India 113 21.7% Psoriasis 103 29.16% 
Mattoo  2002 (30) India 113 18.8%    
 Bashir  2010 (40) Pakistan 9 44.4%    
PAS (Urdu version) Ahmed  2007 (33) 
 
Pakistan 100 15%    
SDS  Saleh  2008 (35) Egypt 50 24% Psoriasis 50 30% 
Alopecia Areata 50 16% 
HDRS Ramakrishna  2014 (48) 
 
India 53 56.6%    
Mahsa  2015 (50) 
 
Iran 110 52.7%    
CLINICAL EXAMINATION BY A 
PSYCHIATRIST 
Vilella  1998 (26) Cuba 22 40.9% Neurotic controls 22 13.6% 
Arycan 2008 (34) Turkey 113 32.7%    
CPRS (MADRS) Mechri  2006 (32) 
 
France 60 18.3% Non vitiligo dermatoses 60 0% 
MMPI Delfino  1988 (25) Italy 10 20% Alopecia Areata 30 Not Stated 
Acne 10 Not Stated 
Psoriasis 10 Not Stated 
Healthy controls 10 Not Stated 
IPQ AlGhamdi  2010 (39)  Saudi 
Arabia 
164 54%    
ES-Q Karelson  2012 (45) Estonia 54 20% Psoriasis 57 42% 
Healthy controls 57 Not Stated 
QUESTIONNAIRE (NO FURTHER DETAILS 
GIVEN)  
Porter  1987 (24) USA 326 7%    
Centre for Epidemiologic Studies Depression scale (CES-D),  Hamilton Depression Rating Scale (HDRS), Hospital Anxiety and Depression Scale (HADS), General Health Questionnaire (GHQ) 
Emotional State Questionnaire (ES-Q), Structured clinical interview for DSM – IV Axis 1 Disorders (Clinical Version) (SCID-1), Sheehan Disability Scale (SDS), Illness Perception Questionnaire 
(IPQ),  Self rating Depression Scale (SDS), Impact of Skin Disease Scale (IMPACT), Comprehensive Psychopathological Rating Scale (CPRS) (which comprises of Montgomery Asberg Depression 
Rating Scale (MADRS), MMPI (a Multi-factorial Method for Personality Investigations), International statistical Classification of Disease version 10 (ICD)-10, Psychiatric Assessment Schedule (PAS), 
Multi-factorial Method for Personality Investigations(MMPI).
TABLE 3: PREVALENCE OF ANXIETY 
 
OUTCOME SCREENING TOOL STUDY COUNTRY VITILIGO 
PARTICIPANTS 
(SAMPLE SIZE) 
PREVALENCE COMPARATORS SAMPLE SIZE 
(COMPARATORS) 
PREVALENCE 
IN 
COMPARATORS 
HADS Ajose  2014 (47) Nigeria 102 48% Albinism (with severe 
complications) 
34 54% 
Albinism (without 
severe complications) 
53 4% 
Alshahwan  2015 (49) Saudi Arabia 64 26.6%    
Tsintsadze  2015 (52) Georgia 15 66.7% Acne 37 78.4% 
Alopecia Areata 28 64.3% 
Psoriasis 36 83.3% 
Neurodermatosis 18 55.5% 
Scabies 23 39% 
Eczema 30 73.3% 
DSM-IV/SCID-1 Balaban  2011 (42) Turkey 42 4.8% Healthy comparators 33 3.0% 
 Sharma  2001 (29) India 30 3.3% Psoriasis 30 3.3% 
 Karia  2015 (51) 
 
India 50 8% Healthy Comparators 50 4% 
HAM-A Mechri  2006 (32) 
 
France 60 20% Non Vitiligo 
dermatoses 
60 0% 
CLINICAL EXAMINATION BY 
PSYCHIATRIST 
Vilella  1998 (26) Cuba 22 68.1% Neurotic controls 22 31.8% 
Arycan  2008 (34)   Turkey 113 15.9%    
PAS (Urdu version) Ahmed  2007 (33) 
 
Pakistan 100 10%    
TAYLOR MANIFEST ANXIETY 
SCALE (ARABIC VERSION) 
Saleh  2008 (35) Egypt 50 14% Psoriasis 50 12% 
Alopecia Areata 50 24% 
IPQ AlGhamdi  2010 (39)  Saudi Arabia 164 57%    
ES-Q Karelson  2012 (45) Estonia 54 22% Psoriasis 57 33% 
Healthy Comparators 57 Not Stated 
Hospital Anxiety and Depression Scale (HADS), Hamilton Anxiety Rating Scale f(HAM – A), , Emotional State Questionnaire (ES-Q), Diagnostic and Statistical Manual of mental disorders, 4th Edition 
(DSM – IV) criteria, Structured clinical interview for DSM – IV Axis 1 Disorders (Clinical Version) (SCID-1), Illness Perception Questionnaire (IPQ),  Psychiatric Assessment Schedule (PAS),  Taylor 
Manifest Anxiety Scale (TMAS),
 TABLE 4: PREVALENCE OF OTHER PSYCHOLOGICAL OUTCOMES 
DISORDERS STUDY COUNTRY
  
VITILIGO 
PARTICIPANTS 
(SAMPLE SIZE) 
PREVALENCE COMPARATORS SAMPLE SIZE 
(COMPARATORS) 
PREVALENCE 
(COMPARATORS) 
OUTCOME SCREENING TOOL 
         
SUBSTANCE ABUSE Karia  2015 () 
 
India 50 10% Healthy 
Comparators 
50 0% DSM – IV criteria 
SUICIDAL 
ATTEMPTS 
Sharma 2001 
(29) 
India 30 3.3% Psoriasis 30 3.3% DSM – IV 
Saleh  2008 (35) Egypt 50 2% Psoriasis 50 4% DSM – IV 
Alopecia Areata 50 2% 
PANIC DISORDER Karelson 2012 
(45) 
Estonia 54 2% Psoriasis 57 Not Stated ES-Q 
Healthy 
Comparators 
57 Not Stated 
Ramakrishna 
2014 (48) 
India 53 11.3%    RSES 
SOCIAL PHOBIA Ahmed  2007 
(33) 
Pakistan 100 8%     GHQ. PAS (Urdu Version) 
Balaban 
2011(42), 
Turkey 42 2.4% Healthy 
Comparators 
33 0% GHQ, SCID-I 
Karelson 2012 
(45),    
Estonia 54 7% Psoriasis 57 Not stated ES-Q 
Healthy  
comparators 
57 Not Stated 
Ramakrishna 
2014 (48) 
India 53 67.9%    RSES 
DYSTHMIC 
DISORDER 
Mattoo  2001 (28) India 113 8.7% Psoriasis 103 4.2% GHQ, CPRS(MADRS), ICD-10 
Mattoo  2002 (30) India 113 6.25%    GHQ, CPRS(MADRS), ICD-10 
Balaban  2011 
(42) 
Turkey 42 4.8% Healthy 
Comparators 
33 0% GHQ, SCID-I 
ADJUSTMENT 
DISORDER 
Mattoo  2001 (28) 
 
India 113 56.52% Psoriasis 103 62.5% GHQ, CPRS(MADRS), ICD-10, DAQ, 
IMPACT 
Mattoo  2002 
(30), 
India 113 75%    GHQ, CPRS(MADRS), ICD-10, DAQ, 
IMPACT 
ALCOHOL 
ADDICTION  
Balaban  2011 
(42) 
Turkey 42 2.4% Healthy 
Comparators 
33 0% GHQ, SCID-I 
ASTHENIA Karelson  2012 
(45) 
Estonia 54 41% Psoriasis 57 65%  ES-Q 
Healthy 
Comparators 
57 Not Stated 
INTERPERSONAL 
CONFLICT 
Sharma  2001 
(29) 
India 30 3.3% Psoriasis 30 3.3% GHQ, DSM – IV 
INSOMNIA Vilella 1998 (26) Cuba 22 22.7% Neurotic controls 22 9% Clinical examination by psychiatrist 
Sharma  2001 
(29) 
India 30 20% Psoriasis 30 56.7% GHQ 
Karelson  2012 
(45) 
Estonia 54 30% Psoriasis 57 Not stated ES-Q 
Healthy 
Comparators 
57 Not Stated  
OBSESSIVE 
COMPULSIVE 
DISORDER  
Ramakrishna 
2014 (48) 
India 53 51%    RSES 
SPECIFIC PHOBIA Balaban  2011 
(42) 
Turkey 42 2.4% Healthy 
Comparators 
33 0% GHQ, SCID-I 
AGORAPHOBIA Ahmed  2007 
(33) 
Pakistan 100 2%    GHQ, PAS, DAQ 
Hospital Anxiety and Depression Scale (HADS), Diagnostic and Statistical Manual of mental disorders, 4th Edition (DSM – IV) criteria, Comprehensive Psychopathological Rating Scale (CPRS) (which 
comprises of Montgomery Asberg Depression Rating Scale (MADRS), Dysfunction Analysis Questionnaire (DAQ), Impact of Skin Disease Scale (IMPACT), International statistical Classification of 
Disease and related health problems (ICD)-10, General Health Questionnaire (GHQ), Structured Clinical Interview for DSM – IV Axis 1 Disorders (Clinical Version) (SCID-1), Rosenberg Self Esteem 
Scale (RSES), Psychiatric Assessment Schedule (PAS), Emotional State Questionnaire (ES-Q ). 
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Supporting Information 
 
SUPPLEMENTARY TABLE 1: SEARCH TERMS FOR MEDLINE (OVID 
MEDLINE (R) IN PROCESS AND OTHER NON-INDEXED CITATIONS AND 
OVID MEDLINE (R) 1946 TO PRESENT) 
S/NO SEARCH TERM 
1 Exp vitiligo/ 
2 Vitiligo.mp.  
3 Leucoderma.mp.   
4 Leukoderma.mp.  
5 1 or 2 or 3 or 4  
6 Exp “Quality of life”/  
7 Exp mental health/   
8 Exp psychology/   
9 Exp depression/   
10 Exp depressive disorder/ 
11 Exp anxiety/   
12 Exp social stigma/   
13 Depress*.mp 
14 Antidepress*.mp 
15 Anti-depress*.mp 
16 Psychosocial*.mp.   
17 Psychology.mp.   
18 Psychological*.mp. 
19 “Quality of Life”.mp. 
20 Depression.mp.   
21 Anxiety.mp.   
22 Stigma* 
23 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
or 20 or 21 or 22 
24 5 and 23 
 
 
SUPPLEMENTARY TABLE 2A: QUALITY ASSESSMENT TOOL 
(COHORT AND CROSS SECTIONAL STUDIES) 
S/NO CRITERIA YES NO NA, NR, CD* 
1 Was the research question or objective in the paper 
clearly stated? 
   
2 Was the study population clearly specified and 
defined? 
   
3 Was the sample somewhat or a true representative of 
the average vitiligo affected population in that 
environment/community? 
   
4 Were all the subjects selected or recruited from the 
same or similar populations (including the same time 
period)? Was there a description of the derivation of 
the non exposed cohort?  
   
5 Were inclusion and exclusion criteria for being in the 
study pre-specified and applied uniformly to all 
participants?  
   
6 Was a sample size justification, power description, or 
variance and effect estimates provided?  
   
8 Was there sufficient timeframe to be able to see an 
association between the exposure and the outcome? 
   
8 Was there a demonstration that the outcome of 
interest was not present before the manifestation of 
vitiligo? 
   
9 Did the study examine different levels/proportion of 
the vitiligo as related to the outcome (e.g., 
categories/severity of outcome)? 
   
10 Were the exposure measures (independent variables) 
clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
   
11 Were the outcome measures (dependent variables) 
clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
   
QUALITY RATING (GOOD, FAIR OR POOR) 
Reviewer #1  
Reviewer #2  
 
*CD, cannot determine; NA, not applicable; NR, not reported 
 
 
 
 
 
 
 
SUPPLEMENTARY TABLE 2B: QUALITY ASSESSMENT TOOL (CASE 
CONTROL STUDIES) 
S/NO CRITERIA YES NO NA, NR, CD* 
1 Was the research question or objective in the paper 
clearly stated? 
   
2 Was the study population clearly specified and 
defined? 
   
3 Was there a clear definition of the cases? Were they 
differentiated from controls?  
   
4 Did the authors include a sample size justification?    
5 Were controls selected or recruited from the same or 
similar population that gave rise to the cases 
(including the same timeframe)? Were they clearly 
defined?  
   
6 Were the definitions, inclusion and exclusion criteria, 
algorithms or processes used to identify or select cases 
and controls valid, reliable, and implemented 
consistently across all study participants? 
   
7 If less than 100 percent of eligible cases and/or 
controls were selected for the study, were the cases 
and/or controls randomly selected from those eligible? 
   
8 Were the investigators able to confirm that the 
exposure/risk occurred prior to the development of the 
condition or event that defined a participant as a case? 
   
9 Were the measures of exposure clearly defined, valid, 
reliable, and implemented consistently (including the 
same time period) across all study participants? 
   
10 Was there use of concurrent controls?    
11 Were the outcome measures (dependent variables) 
clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
   
QUALITY RATING (GOOD, FAIR OR POOR) 
Reviewer #1  
Reviewer #2  
 
*CD, cannot determine; NA, not applicable; NR, not reported 
 
 
 
 
 
 
 
 
 
Figure Legends 
 
Figure 1: Summary of study selection process 
Figure 2: Meta-analyses of the prevalence of depression measured by (1) Depression-specific tools; 
(2) Non-depression specific tools and (3) Clinical Examination 
Figure 3: Meta-analysis of the prevalence of depression in people with vitiligo compared to those 
with psoriasis 
Figure 4: Meta-analyses of the prevalence of anxiety measured by (1) Anxiety-specific tools; (2) 
Non-anxiety specific tools and (3) Clinical Examination 
Figure 5: Meta-analysis of the prevalence of anxiety in people with vitiligo compared to those with 
psoriasis 
 
 
 
 
 
